Spartan Bioscience 'lab-in-a-box' test kit finally cleared for COVID-19 battle 渥太华生物高科技测试盒新进展

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
22,564
荣誉分数
5,343
声望点数
373

Spartan Bioscience 'lab-in-a-box' test kit finally cleared for COVID-19 battle​

"This is going to be a game-changer in making diagnoses and helping to open the economy."
Author of the article: James Bagnall
Publishing date: Jan 23, 2021 • 20 hours ago • 4 minute read

Paul Lem, CEO of Spartan Bioscience Inc. in Ottawa, sits beside the tiny square machine the local company has developed that analyzes DNA.  It is the world's smallest DNA analyzer.  Julie Oliver/Postmedia


Dr. Paul Lem, co-founder and chief medical officer for Spartan Bioscience Inc. in Ottawa. PHOTO BY JULIE OLIVER /Postmedia

Assuming no further hiccups, Spartan looks to be on track to top $200 million in revenues this year based on government orders alone. Its technology is also well-suited for use by airlines and private businesses anticipating reopening. “We are still ramping up R&D because this is a huge and significant opportunity,” said Roger Eacock, Spartan’s CEO since October. “We have buyers already lined up,” he added in reference to private-sector customers.

OTTAWA - Jan. 2021 - Spartan Bioscience co-founder, Dr. Jamie Spiegelman, a senior staff doctor at Humber River Regional Hospital. Handout


Spartan Bioscience co-founder, Dr. Jamie Spiegelman, a senior staff doctor at Humber River Regional Hospital. Supplied PHOTO BY SPARTAN BIOSCIENCE INC. /Handout

OTTAWA - Jan. 2021 -  Roger Eacock, the CEO of Spartan Bioscience. Handout


Roger Eacock, the CEO of Spartan Bioscience. PHOTO BY SPARTAN BIOSCIENCE INC. /Handout

Eacock stressed that Spartan would fulfill its commitments to governments as a first priority, but added he believed there was enough flexibility in production to serve private-sector firms at the same time.

Alberta, Ontario, Quebec and the federal government last spring ordered nearly two million test cartridges and the Cube devices that process them — approaching $200 million worth of potential business with more to follow, all of it contingent on the performance of the initial samples and Health Canada approval. With this in hand, Spartan can start making good on those initial purchase orders.

In retrospect, Spartan pushed its technology faster than it should have, no doubt influenced by the intensity of the first wave of COVID-19 and the urgent need for portable tests. Quite simply, Spartan’s early method of collecting nasal samples didn’t pick up sufficient quantities of the virus for accurate tests.

Spiegelman, who has more than a passing interest in Spartan’s breakthrough, has some thoughts about that. He is a co-founder with Paul and John Lem and a board member. Spiegelman is also a physician at Humber River Regional Hospital in the epicentre of Toronto’s COVID-19 outbreak. That makes him desperate to get COVID-19 tests done quickly and accurately.

The physician said he was not consulted by the firm on the design of the initial test kit submitted for Health Canada’s inspection. Spiegelman knows the viral load is heaviest deep in the back of the throat, thus requiring lengthy nasal swabs for good samples, but Spartan early on submitted its shorter, proprietary swab as part of the package.

“It didn’t get big enough samples of the virus,” Spiegelman said. Not only that, he added, the test kit’s chemicals had to be kept frozen while in transit, thus introducing complications to the supply chain and making deliveries to remote regions more difficult.

Spartan Bioscience rapid-testing device for COVID-19. Photo courtesy of AHS ORG XMIT: POS2003301454432181


The Spartan Bioscience rapid-testing device for COVID-19. PHOTO BY AHS

The good news was that Spartan’s DNA-analyzing technology was solid, so the company opted to remake the test kits to rely on longer, standard-issue swabs and a storage solution that worked at room temperature. It was a significant R&D effort.

The result is a product that does not require a lot of training to use and that can be adapted to testing future viruses.

“I taught my five-year-old daughter to use this in five minutes,” Spiegelman said.

While portable DNA analyzers are generally less accurate than lab-based technology, the efficacy of the Cube now seems well suited for the fight against COVID-19, which demands rapid results. Spiegelman said the clinical trials suggested a positive COVID-19 test result on the Cube is nearly certain to be accurate, while a negative result is 80 per cent to 90 per cent likely to be accurate.

If these kinds of results play out in the months to come, Spartan can afford to contemplate a future beyond one dominated by COVID-19. Because the Cube analyzes DNA, it could be adapted to test for other viruses.

Next time, however, you can be sure the company will be sure of its ground before engaging Health Canada’s regulators.

 

Hard Worker

知名会员
注册
2012-08-31
消息
3,142
荣誉分数
939
声望点数
173
疫苗都出来半年了,一个检测试剂还没搞定,厉害了,我的加拿大!
 

JClub

初级会员
注册
2019-01-31
消息
174
荣誉分数
121
声望点数
53
其它国家有这种一个小时出结果的移动检测盒吗? 没听说过,也许只是我不知道。

“While portable DNA analyzers are generally less accurate than lab-based technology, the efficacy of the Cube now seems well suited for the fight against COVID-19, which demands rapid results. Spiegelman said the clinical trials suggested a positive COVID-19 test result on the Cube is nearly certain to be accurate, while a negative result is 80 per cent to 90 per cent likely to be accurate.”

这个准确率到底是多高呢?看不太懂。我的理解是,如果结果是阳性,准确率100%; 如果结果是阴性,有10-20% 可能性是阳性漏检。
 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
22,564
荣誉分数
5,343
声望点数
373
其它国家有这种一个小时出结果的移动检测盒吗? 没听说过,也许只是我不知道。

“While portable DNA analyzers are generally less accurate than lab-based technology, the efficacy of the Cube now seems well suited for the fight against COVID-19, which demands rapid results. Spiegelman said the clinical trials suggested a positive COVID-19 test result on the Cube is nearly certain to be accurate, while a negative result is 80 per cent to 90 per cent likely to be accurate.”

这个准确率到底是多高呢?看不太懂。我的理解是,如果结果是阳性,准确率100%; 如果结果是阴性,有10-20% 可能性是阳性漏检。
不是很懂,如果是这样,也算不错了。假阴性大概多是因为采集样品时,病毒浓度不够,仪器灵敏度无法确诊阳性。这个问题对于现在很多核酸测试都有可能存在。
 

wei_cheng

围观真实的科技新闻是一大乐趣
注册
2018-05-30
消息
1,140
荣誉分数
501
声望点数
123
串普也演示过一种。Spartan Cube 会有偏远地区的订单。Better late than never。
True positive rate = TP/(TP+FP) 接近 100%,因此 false positive rate 很低
True negative rate = TN/(TN+FN) 大概 80-90%,因此 false negative rate 大概10-20%
Diagnostic accuracy 指的是 sensitivity = TP/(TP+FN), specificity=TN/(TN+FP)
其它国家有这种一个小时出结果的移动检测盒吗? 没听说过,也许只是我不知道。

“While portable DNA analyzers are generally less accurate than lab-based technology, the efficacy of the Cube now seems well suited for the fight against COVID-19, which demands rapid results. Spiegelman said the clinical trials suggested a positive COVID-19 test result on the Cube is nearly certain to be accurate, while a negative result is 80 per cent to 90 per cent likely to be accurate.”

这个准确率到底是多高呢?看不太懂。我的理解是,如果结果是阳性,准确率100%; 如果结果是阴性,有10-20% 可能性是阳性漏检。
 
最后编辑:

cable4sale

知名会员
注册
2004-09-11
消息
2,575
荣誉分数
284
声望点数
193

Spartan Bioscience Receives Health Canada Authorization for Made-In-Canada Rapid COVID-19 Test​

January 23rd, 2021

Spartan Bioscience announced today it has received approval from Health Canada and is now authorized to sell the Spartan COVID-19 System, a rapid, on-site molecular diagnostic test for the qualitative detection of SARS-CoV-2, the virus causing COVID-19. S...
 

Hard Worker

知名会员
注册
2012-08-31
消息
3,142
荣誉分数
939
声望点数
173
这个公司已经在油管上打了半年多的广告了,关键词就是加拿大政府支持的公司,估计又是一个政府腐败的产物。
 

jy

资深人士
注册
2015-03-14
消息
5,439
荣誉分数
1,102
声望点数
223

Spartan Bioscience 'lab-in-a-box' test kit finally cleared for COVID-19 battle​

"This is going to be a game-changer in making diagnoses and helping to open the economy."
Author of the article: James Bagnall
Publishing date: Jan 23, 2021 • 20 hours ago • 4 minute read

Paul Lem, CEO of Spartan Bioscience Inc. in Ottawa, sits beside the tiny square machine the local company has developed that analyzes DNA.  It is the world's smallest DNA analyzer.  Julie Oliver/Postmedia's smallest DNA analyzer.  Julie Oliver/Postmedia


Dr. Paul Lem, co-founder and chief medical officer for Spartan Bioscience Inc. in Ottawa. PHOTO BY JULIE OLIVER /Postmedia

Assuming no further hiccups, Spartan looks to be on track to top $200 million in revenues this year based on government orders alone. Its technology is also well-suited for use by airlines and private businesses anticipating reopening. “We are still ramping up R&D because this is a huge and significant opportunity,” said Roger Eacock, Spartan’s CEO since October. “We have buyers already lined up,” he added in reference to private-sector customers.

OTTAWA - Jan. 2021 - Spartan Bioscience co-founder, Dr. Jamie Spiegelman, a senior staff doctor at Humber River Regional Hospital. Handout


Spartan Bioscience co-founder, Dr. Jamie Spiegelman, a senior staff doctor at Humber River Regional Hospital. Supplied PHOTO BY SPARTAN BIOSCIENCE INC. /Handout

OTTAWA - Jan. 2021 -  Roger Eacock, the CEO of Spartan Bioscience. Handout


Roger Eacock, the CEO of Spartan Bioscience. PHOTO BY SPARTAN BIOSCIENCE INC. /Handout

Eacock stressed that Spartan would fulfill its commitments to governments as a first priority, but added he believed there was enough flexibility in production to serve private-sector firms at the same time.

Alberta, Ontario, Quebec and the federal government last spring ordered nearly two million test cartridges and the Cube devices that process them — approaching $200 million worth of potential business with more to follow, all of it contingent on the performance of the initial samples and Health Canada approval. With this in hand, Spartan can start making good on those initial purchase orders.

In retrospect, Spartan pushed its technology faster than it should have, no doubt influenced by the intensity of the first wave of COVID-19 and the urgent need for portable tests. Quite simply, Spartan’s early method of collecting nasal samples didn’t pick up sufficient quantities of the virus for accurate tests.

Spiegelman, who has more than a passing interest in Spartan’s breakthrough, has some thoughts about that. He is a co-founder with Paul and John Lem and a board member. Spiegelman is also a physician at Humber River Regional Hospital in the epicentre of Toronto’s COVID-19 outbreak. That makes him desperate to get COVID-19 tests done quickly and accurately.

The physician said he was not consulted by the firm on the design of the initial test kit submitted for Health Canada’s inspection. Spiegelman knows the viral load is heaviest deep in the back of the throat, thus requiring lengthy nasal swabs for good samples, but Spartan early on submitted its shorter, proprietary swab as part of the package.

“It didn’t get big enough samples of the virus,” Spiegelman said. Not only that, he added, the test kit’s chemicals had to be kept frozen while in transit, thus introducing complications to the supply chain and making deliveries to remote regions more difficult.

Spartan Bioscience rapid-testing device for COVID-19. Photo courtesy of AHS ORG XMIT: POS2003301454432181


The Spartan Bioscience rapid-testing device for COVID-19. PHOTO BY AHS

The good news was that Spartan’s DNA-analyzing technology was solid, so the company opted to remake the test kits to rely on longer, standard-issue swabs and a storage solution that worked at room temperature. It was a significant R&D effort.

The result is a product that does not require a lot of training to use and that can be adapted to testing future viruses.

“I taught my five-year-old daughter to use this in five minutes,” Spiegelman said.

While portable DNA analyzers are generally less accurate than lab-based technology, the efficacy of the Cube now seems well suited for the fight against COVID-19, which demands rapid results. Spiegelman said the clinical trials suggested a positive COVID-19 test result on the Cube is nearly certain to be accurate, while a negative result is 80 per cent to 90 per cent likely to be accurate.

If these kinds of results play out in the months to come, Spartan can afford to contemplate a future beyond one dominated by COVID-19. Because the Cube analyzes DNA, it could be adapted to test for other viruses.

Next time, however, you can be sure the company will be sure of its ground before engaging Health Canada’s regulators.


CBC的新闻里也没说从上次拒绝批准到今天批准,斯巴达的产品有啥进步,只是说斯巴达说原来用的swab不好,没采到足够的病毒。
我觉得虽然理论上有这个可能,但这个解释还是太牵强。一个swab的问题能折腾这么长时间?从去年5月份一直到现在?
是不是加拿大政府实在着急了,拉到篮子里就是菜?
 

Hard Worker

知名会员
注册
2012-08-31
消息
3,142
荣誉分数
939
声望点数
173
CBC的新闻里也没说从上次拒绝批准到今天批准,斯巴达的产品有啥进步,只是说斯巴达说原来用的swab不好,没采到足够的病毒。
我觉得虽然理论上有这个可能,但这个解释还是太牵强。一个swab的问题能折腾这么长时间?从去年5月份一直到现在?
是不是加拿大政府实在着急了,拉到篮子里就是菜?
这公司在广告里说了是拿加拿大政府funding 的,估计钱花完了,现在没法交帐,只好瞎吹了。
 

jy

资深人士
注册
2015-03-14
消息
5,439
荣誉分数
1,102
声望点数
223
这公司在广告里说了是拿加拿大政府funding 的,估计钱花完了,现在没法交帐,只好瞎吹了。
看到有人说南韩早就在用,不知真假。不过南韩办事粗糙,可能对误报率不在乎,能有一半对就满意?或者是宁可误杀一千,绝不放过一个?
 

changyang

初级会员
注册
2014-03-23
消息
768
荣誉分数
136
声望点数
53
Spartan公司在去年春季时就推出了一种快速检测仪,该公司合伙创始人兼首席医学官保罗·林(Paul Lem)是一位同时拥有多伦多大学人类生物学学士学位和渥太华大学医学学位的华裔男子。

图片
(JULIE OLIVER /Postmedia)

虽然这款检测仪当时就曾获得联邦卫生部的批准,但后来卫生部又提出了一些保留意见,Spartan公司自愿召回向联邦政府送交的5500个快速便携检测仪,并表示要做进一步的研究,以找到问题根源并加以修复。

当时Spartan公司还表示,联邦卫生部是对该款检测仪所使用的获取被检测者脱氧核糖核酸DNA的拭子有疑虑。

经过进一步研究和改进,Spartan近期推出的新款检测仪所使用的就是“普通鼻咽拭子”,而非该公司自己设计的拭子。联邦卫生部表示,这样一来,新检测仪在安全性和有效性方面就都符合了卫生部的要求。

另一位合伙创始人Jamie Spiegelman表示,新款检测仪是把实验室浓缩进了一个咖啡杯大小的盒子里,而且不需要特别的拭子就能进行检测。
 

Hard Worker

知名会员
注册
2012-08-31
消息
3,142
荣誉分数
939
声望点数
173
看到有人说南韩早就在用,不知真假。不过南韩办事粗糙,可能对误报率不在乎,能有一半对就满意?或者是宁可误杀一千,绝不放过一个?
不知道谁用,反正现在检测试剂早就不是什么新东西了。现在的关键是咽拭子可能无法提取到准确的组织,国内可能要用肛拭子提高准确率。拭目以待吧!
 

jy

资深人士
注册
2015-03-14
消息
5,439
荣誉分数
1,102
声望点数
223
不知道谁用,反正现在检测试剂早就不是什么新东西了。现在的关键是咽拭子可能无法提取到准确的组织,国内可能要用肛拭子提高准确率。拭目以待吧!
这公司主推的是盒子吧?
 

JClub

初级会员
注册
2019-01-31
消息
174
荣誉分数
121
声望点数
53
今天早上听AM580 news quiz,
Question: which Canadian company provides the rapid covid test box?
Answer: the game changer :D
 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
22,564
荣誉分数
5,343
声望点数
373
A sniffer dog is trained by a French firefighter to detect the coronavirus in Libourne on January 29, 2021 as part of a joint operation between the Bordeaux CHU and the CEVA animal health company to provide a method enabling the use of trained dogs in combatting the spread of the Covid-19 pandemic caused by the novel coronavirus. - The dogs sniff at various samples with COVID-19 scents, negative samples, and fake samples. (Photo by PHILIPPE LOPEZ / AFP) (Photo by PHILIPPE LOPEZ/AFP via Getty Images)
A sniffer dog guided by a firefighter smells samples in Libourne, France on Friday. Bordeaux health officials, in conjunction with a veterinary company, are seeing if the dogs can be used in the pandemic. There is some evidence, though not peer-reviewed, that dogs can detect virus scents and negative samples. (Philippe Lopez/AFP/Getty Images)​

低科技测试法即将研制成功。
 
顶部